MedTrace Logo

Real World Study on the Use of Cemiplimab in Adult Patients in UK

NCT05493826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2023-07-14

No results posted yet for this study

Summary

The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.

Conditions

Interventions

OTHER

No intervention

Non-interventional study based on secondary use of hospital medical record

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences and Operations · Sanofi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493826 on ClinicalTrials.gov